Drupanin

Drupanin

SCHEMBL3680290

CC(C)=CCc1cc(/C=C/C(=O)O)ccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 13/20 1.00
AKR1B10 O60218 3/20 1.00
AKR1B1 P15121 3/20 1.00
MMP2 P08253 2/20 0.71
PAK1 Q13153 1/20 0.71
AKR1C2 P52895 11/20 0.67
PTPN1 P18031 4/20 0.67
PTGS1 P23219 1/20 0.65
PTGS2 P35354 1/20 0.65
MGAM O43451 1/20 0.61
MAOA P21397 1/20 0.61
MAOB P27338 1/20 0.61
XDH P47989 1/20 0.61
HTT P42858 1/20 0.57
KDM4E B2RXH2 2/20 0.57
HSD17B10 Q99714 2/20 0.57
MEN1 O00255 1/20 0.57
HDAC3 O15379 1/20 0.57
CA12 O43570 1/20 0.57
ALDH1A1 P00352 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Drupanin SCHEMBL5144749 1.00 AKR1C3 (1.00) AKR1C3AKR1B10AKR1B1MMP2PAK1
Drupanin SCHEMBL20472013 0.93 AKR1C3 (0.87) AKR1C3AKR1B10AKR1B1MMP2PAK1
Plicatin B SCHEMBL1227605 0.85 AKR1C3 (0.73) AKR1C3AKR1B10AKR1B1MMP2PAK1
Artepillin SCHEMBL1229229 0.83 AKR1C3 (1.00) AKR1C3AKR1B10AKR1B1MMP2PAK1
Artepillin SCHEMBL2138507 0.83 AKR1C3 (1.00) AKR1C3AKR1B10AKR1B1MMP2PAK1
Artepillin SCHEMBL7128580 0.83 AKR1C3 (1.00) AKR1C3AKR1B10AKR1B1MMP2PAK1
SCHEMBL10632283 0.83 AKR1C3 (0.70) AKR1C3AKR1B10AKR1B1MMP2PAK1
Stipulin SCHEMBL29435847 0.82 PTPN1 (0.88) AKR1C3AKR1B10AKR1B1MMP2PAK1
Stipulin SCHEMBL633709 0.82 PTPN1 (0.88) AKR1C3AKR1B10AKR1B1MMP2PAK1
SCHEMBL30384586 0.82 PTPN1 (0.74) AKR1C3AKR1B10AKR1B1PTPN1PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680720-A1 OPTIMIZED PRODUCTION OF BRANCH POINT COMPOUNDS AND DERIVATIVES USING ALTERNATIVE ISOPENTENYL DIPHOSPHATE-SUPPLYING PATHWAYS EvodiaBio ApS (DK) 2026-01-21 EP claimed
US-12529077-B2 Production of geranyl diphosphate-derived compounds Københavns Universitet (DK) 2026-01-20 US claimed
CN-119899829-A Yarrowia lipolytica engineering bacterium for producing isopentenyl aromatic compound, construction method and application thereof 山东大学 2025-04-29 CN claimed
US-20250041354-A1 METHOD FOR TREATING BURN PAIN IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2025-02-06 US claimed
US-12150964-B1 Subcutaneous injection method for pain treatment IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2024-11-26 US claimed
US-20240374653-A1 SUBCUTANEOUS INJECTION METHOD FOR PAIN TREATMENT IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2024-11-14 US claimed
WO-2024189183-A1 OPTIMIZED PRODUCTION OF BRANCH POINT COMPOUNDS AND DERIVATIVES USING ALTERNATIVE ISOPENTENYL DIPHOSPHATE-SUPPLYING PATHWAYS EVODIABIO APS (DK) 2024-09-19 WO claimed
US-12076349-B1 Method for treating burns with brazilian green propolis IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2024-09-03 US claimed
US-20240277777-A1 METHOD FOR TREATING BURNS WITH BRAZILIAN GREEN PROPOLIS IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2024-08-22 US claimed
US-11998572-B2 Method for treating nociceptive pain and burns with brazilian green propolis alcohol extract IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2024-06-04 US claimed
CN-114377006-B Absorption promoter for cinnamic acid derivative 株式会社山田养蜂场本社 2024-02-09 CN claimed
US-20230159960-A1 Production Of Geranyl Diphosphate-Derived Compounds KOBENHAVNS UNIVERSITET (DK) 2023-05-25 US claimed
EP-4133063-A1 PRODUCTION OF GERANYL DIPHOSPHATE-DERIVED COMPOUNDS Københavns Universitet (DK) 2023-02-15 EP claimed
CN-115698272-A Production of geranyl diphosphate derived compounds 哥本哈根大学 2023-02-03 CN claimed
US-20220105054-A1 ABSORPTION ENHANCER OF CINNAMIC ACID DERIVATIVE YAMADA BEE COMPANY, INC. (JP) 2022-04-07 US claimed
WO-2009111848-A1 EXTRACTS OF BACCHARIS SP. OR GREEN PROPOLIS FOR USE AS SANITIZER UNIVERSIDADE DE SÃO PAULO - USP (BR) 2009-09-17 WO claimed
US-20060110520-A1 Active oxygen eliminator derived from natural substance and use thereof MIDORIKAWA KIYOSHI 2006-05-25 US claimed
EP-1621194-A1 ACTIVE OXYGEN ELIMINATOR ORIGINATING IN NATURAL MATERIAL AND USE OF THE SAME Nihon Propolis Co., Ltd. (JP) 2006-02-01 EP claimed
JP-60163841-A None JP disclosed
JP-S60163841-A 3-(4-HYDROXYPHENYL)-2-(E)-PROPENIC ACID RES INST FOR PROD DEV 1985-08-26 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12529077-B2 Production of geranyl diphosphate-derived compounds GGPS1, OGA, GBA3 AKR1C3 253/4885AKR1B10 575/4885AKR1B1 439/4885
US-20220105054-A1 ABSORPTION ENHANCER OF CINNAMIC ACID DERIVATIVE FABP2, SLC16A3, SLC16A7 AKR1C3 261/4885AKR1B10 583/4885AKR1B1 363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.